Riskpilot← Back to searchSign inGet full accessNevada Pharma AB
ABActiveOrg 5566744933Sveavägen 9Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20051 employees
Revenue 2024
SEK 4
EBITDA margin
-5394125.0%
+20% vs 2023
Equity ratio
86.6%
Financial strength
Net profit 2024
SEK 164K
-96% vs 2023
| Revenue | SEK 4 | — |
| EBITDA | SEK -216K | +20% |
| Net profit | SEK 164K | -96% |
| Total assets | SEK 16,4M | -6% |
| Equity | SEK 14,2M | +1% |
| Employees | 1 | — |
Legal name
Nevada Pharma AB
Org number
5566744933
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
14 januari 2005
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Thunell, Carl Staffan Thunell, Linda Birgitta
Company purpose
Bolaget skall bedriva konsultverksamhet och marknadsföring inom medicin och hälsoområdet samt därmed förenlig verksamhet.
Address
Sveavägen 9
Email
staffan.thunell@nevadapharma.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 367 | 0 | 3 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | −0 |
| EBITDA | −700 | −540 | −434 | −211 | −198 | −228 | −168 | −271 | −216 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — |
| EBIT | −700 | −540 | −434 | −211 | −198 | −228 | −168 | −271 | −216 |
| Net financials | 425 | 54 613 | 23 300 | — | 3 492 | 5 285 | 4 095 | 4 000 | 380 |
| Profit before tax | −276 | 54 074 | 23 126 | −211 | 3 295 | 5 057 | 4 247 | 3 729 | 164 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — |
| Net profit | −276 | 54 074 | 23 126 | −211 | 3 295 | 5 057 | 4 247 | 3 729 | 164 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 9 330 | 67 158 | 72 957 | 59 447 | 50 863 | 55 422 | 16 507 | 17 473 | 16 354 |
| Equity | 1 691 | 54 264 | 64 811 | 41 999 | 45 294 | 49 031 | 10 278 | 14 007 | 14 171 |
| Long-term debt | 6 720 | 12 847 | 7 885 | 0 | 0 | 0 | 0 | 3 301 | 2 086 |
| Short-term debt | 919 | 47 | 262 | 17 448 | 5 569 | 6 391 | 6 229 | 165 | 98 |
| Total debt | 7 639 | 12 894 | 8 147 | 17 448 | 5 569 | 6 391 | 6 229 | 3 466 | 2 183 |
EBITDA margin
-5394125.0%
This company
15.8%
Market median
-34140132% vs market
20162024
Equity ratio
86.6%
This company
38.2%
Market median
+127% vs market
20162024
Return on equity
1.2%
This company
18.4%
Market median
-93% vs market
20162024
Net profit margin
4099675.0%
This company
8.1%
Market median
+50613172% vs market
20162024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162024
Debt / equity
0.15×
This company
0.62×
Market median
+76% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-07-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-06-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EA Chief Auditor | Chief Auditor | 2022 | — | — |
CS Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Nevada Pharma AB 
Arex Intressenter ABBoard members of Nevada Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Adrian Emilsson | Chief Auditor | 0 companies |
| Carl Staffan Thunell | Chief Executive Officer | 0 companies |
| Linda Birgitta Thunell | Chairman | 0 companies |
| Sofia Karolina Thunell | Board of Directors | 0 companies |
| Karin Linnea Kärki Thunell | Board of Directors | 0 companies |
| Agnes Johanna Thunell Vera | Board of Directors | 0 companies |